Evidence map›Paper›PMID 36806947›Full record

ArticleCancer medicine2023

Peripheral lymphocytes and lactate dehydrogenase correlate with response and survival in head and neck cancers treated with immune checkpoint inhibitors.

Cassie Pan, Qian Vicky Wu, Jenna Voutsinas, Jeffrey J Houlton, Brittany Barber, Zain H Rizvi, Emily Marchiano, Neal Futran, George E Laramore, Jay J Liao and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Prediction and Prognostication of Peripheral Blood Biomarkers in Head and Neck Cutaneous Squamous Cell Carcinoma.Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery · 2026
    Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 1 country.

Cassie PanDepartment of Otolaryngology-Head and Neck Surgery, University of Washington, Seattle, Washington, USA.ORCID 0000-0003-2776-4679
Qian Vicky WuClinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
Jenna VoutsinasClinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
Jeffrey J HoultonHead & Neck Specialists, Charleston, South Carolina.
Brittany BarberDepartment of Otolaryngology-Head and Neck Surgery, University of Washington, Seattle, Washington, USA.
Zain H RizviDepartment of Otolaryngology-Head and Neck Surgery, University of Washington, Seattle, Washington, USA.
Emily MarchianoDepartment of Otolaryngology-Head and Neck Surgery, University of Washington, Seattle, Washington, USA.
Neal FutranDepartment of Otolaryngology-Head and Neck Surgery, University of Washington, Seattle, Washington, USA.
George E LaramoreDepartment of Radiation Oncology, University of Washington, Seattle, Washington, USA.
Jay J LiaoDepartment of Radiation Oncology, University of Washington, Seattle, Washington, USA.
Upendra ParvathaneniDepartment of Radiation Oncology, University of Washington, Seattle, Washington, USA.
Renato G MartinsDivision of Hematology, Oncology and Palliative Care, Department of Medicine, Virginia Commonwealth University, Richmond, Virginia, USA.
Jonathan R FrommDepartment of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA.
Cristina P RodriguezDivision of Oncology, Department of Medicine, University of Washington, Seattle, Washington, USA.
University of Washington · USFred Hutch Cancer Center · USCarolina Veterinary Specialists · USVirginia Commonwealth University · US

Funding

Research Training in OtolaryngologyT32DC000018 · NIDCD · UNIVERSITY OF WASHINGTON · PI STONE, JENNIFER S. · 1989 to 2023
$7.8M
NIDCD NIH HHS T32 DC000018
6 · The paper itself

Abstract

backgroundLittle is known regarding associations between peripheral blood biomarkers (PBBMs) and survival, response, and toxicity in recurrent/metastatic head and neck squamous cell carcinomas (R/M HNSCC) treated with immune checkpoint inhibitors (ICIs).

methodsIn this single-institution retrospective cohort study, a dataset of patients with R/M HNSCC treated with ICIs between 08/2012-03/2021 was established, including demographic and clinicopathologic characteristics. Pretreatment PBBMs were collected and evaluated for associations with grade ≥3 adverse events (G ≥ 3AE) by CTCAEv5, objective response (ORR) by RECIST 1.1, overall survival (OS), and progression-free survival (PFS). Multivariable models for each outcome were created using elastic net variable selection.

resultsOur study included 186 patients, with 51 (27%) demonstrating complete or partial response to immunotherapy. Multivariable models adjusted for ECOG performance status (PS), p16, and smoking demonstrated that pretreatment higher LDH and absolute neutrophils, as well as lower percent lymphocytes correlated with worse OS and PFS. Higher LDH and lower % lymphocytes also correlated with worse ORR.

conclusionsIn the largest study to date examining PBBMs in ICI-treated R/M HNSCCs, our variable selection method revealed PBBMs prognostic for survival and response to immunotherapy. These biomarkers warrant further investigation in a prospective study along with validation with CPS biomarker.

Indexed as

Head and Neck NeoplasmsImmune Checkpoint InhibitorsBiomarkersHumansL-Lactate DehydrogenaseLymphocytesNeoplasm Recurrence, LocalProspective StudiesRetrospective StudiesSquamous Cell Carcinoma of Head and NeckTreatment OutcomeBiomarkersImmune Checkpoint InhibitorsL-Lactate Dehydrogenasebiomarkerscheck point controlhead and neck cancermedical oncologyprognostic factor

Identifiers

PMID36806947
PMCPMC10166901
OpenAlexW4321445931

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.